TENBAGGER-POTENTIAL: Top-Wirtschaftsmagazin adelt Biotech-Firma und bringt Vergleich mit 7,2 Mrd Übernahme! Absoluter STRONG BUY!
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
TENBAGGER-POTENTIAL***: Top-Wirtschaftsmagazin adelt Biotech-Firma und bringt Vergleich mit 7,2 Mrd Übernahme! Absoluter STRONG BUY!
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
Article content
San Diego, California–(Newsfile Corp. – May 25, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) (“Tryp”), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with Alcami Corporation (“Alcami”), a global pharmaceutical contract development and manufacturing organization (CDMO), to support the proprietary formulation of products for Tryp’s Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program. Tryp’s collaboration with Alcami will initially focus on developing oral formulations for Tryp’s proprietary psilocybin Active Pharmaceutical Ingredient (“API”) being manufactured by Albany Molecular Research, Inc. (“AMRI”). “The support we have been engaged to provide is a testament to our broad capabilities, technical expertise, and ability to collaborate with customers to consistently deliver high quality results,”
by Tyler Durden
Sunday, May 23, 2021 - 08:45 AM
In part one of this two-part series, we unearthed the story behind the prohibition of psychedelic substances, and how strict regulations resulted in a hugely stigmatized industry.
new breakthroughs proving the untapped therapeutic potential of medicinal psychedelics are coming to the fore, leading many to believe that restricting them may have in fact been premature.
The graphic above from Tryp Therapeutics is the last in a two part series that explores how psychedelics have evolved over the last 6,000 years.
The Psychedelic Renaissance
After decades of being labeled as illegal narcotics, the industry reinvented itself as a viable solution for treating hard-to-treat illnesses in a safe and controlled way.